Glycogen synthase kinase-3: a potential preventive target for prostate cancer management.

ABSTRACT:

Objectives

Prostate cancers are the frequently diagnosed cancers in men, and patients with metastatic disease only have 28% chance for 5-year survival. Patients with low-risk tumors are subjected to active surveillance, whereas high-risk cases are actively treated. Unfortunately, there is no cure for patients with late-stage disease. Glycogen synthase kinase-3 (GSK-3, α and β) is a protein serine/threonine kinase and has diverse cellular functions and numerous substrates. We sought to summarize all the studies done with GSK-3 in prostate cancers and to provide a prospective direction for future work.

Methods and materials

A comprehensive search of the literature on the electronic databases PubMed was conducted for the subject terms of GSK-3 and prostate cancer. Gene mutation

SUBMITTER: Li B 

PROVIDER: S-EPMC4753786 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature